Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration

E. Campora, M. Esposito, D. Civalleri, L. Gogioso, F. Decian, N. Balletto, A. Falcone, M. T. Nobile, B. Parodi, S. Cafaggi, G. Bignardi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37°C) dialysate daily for five consecutive days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450±165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatient basis and produces a significant pharmacological advantage over conventional routes of administration.

Original languageEnglish
Pages (from-to)829-832
Number of pages4
JournalAnticancer Research
Volume7
Issue number4 B
Publication statusPublished - 1987

Fingerprint

Ascitic Fluid
Fluorouracil
Urine
Serum
Area Under Curve
Dialysis Solutions
Colonic Neoplasms
Half-Life
Permeability
Outpatients
High Pressure Liquid Chromatography
Pharmacology
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Campora, E., Esposito, M., Civalleri, D., Gogioso, L., Decian, F., Balletto, N., ... Bignardi, G. (1987). Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. Anticancer Research, 7(4 B), 829-832.

Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. / Campora, E.; Esposito, M.; Civalleri, D.; Gogioso, L.; Decian, F.; Balletto, N.; Falcone, A.; Nobile, M. T.; Parodi, B.; Cafaggi, S.; Bignardi, G.

In: Anticancer Research, Vol. 7, No. 4 B, 1987, p. 829-832.

Research output: Contribution to journalArticle

Campora, E, Esposito, M, Civalleri, D, Gogioso, L, Decian, F, Balletto, N, Falcone, A, Nobile, MT, Parodi, B, Cafaggi, S & Bignardi, G 1987, 'Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration', Anticancer Research, vol. 7, no. 4 B, pp. 829-832.
Campora E, Esposito M, Civalleri D, Gogioso L, Decian F, Balletto N et al. Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. Anticancer Research. 1987;7(4 B):829-832.
Campora, E. ; Esposito, M. ; Civalleri, D. ; Gogioso, L. ; Decian, F. ; Balletto, N. ; Falcone, A. ; Nobile, M. T. ; Parodi, B. ; Cafaggi, S. ; Bignardi, G. / Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. In: Anticancer Research. 1987 ; Vol. 7, No. 4 B. pp. 829-832.
@article{a4e5cbc4670e43d9a129798bacdfb2a4,
title = "Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration",
abstract = "Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37°C) dialysate daily for five consecutive days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450±165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatient basis and produces a significant pharmacological advantage over conventional routes of administration.",
author = "E. Campora and M. Esposito and D. Civalleri and L. Gogioso and F. Decian and N. Balletto and A. Falcone and Nobile, {M. T.} and B. Parodi and S. Cafaggi and G. Bignardi",
year = "1987",
language = "English",
volume = "7",
pages = "829--832",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 B",

}

TY - JOUR

T1 - Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration

AU - Campora, E.

AU - Esposito, M.

AU - Civalleri, D.

AU - Gogioso, L.

AU - Decian, F.

AU - Balletto, N.

AU - Falcone, A.

AU - Nobile, M. T.

AU - Parodi, B.

AU - Cafaggi, S.

AU - Bignardi, G.

PY - 1987

Y1 - 1987

N2 - Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37°C) dialysate daily for five consecutive days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450±165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatient basis and produces a significant pharmacological advantage over conventional routes of administration.

AB - Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37°C) dialysate daily for five consecutive days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450±165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatient basis and produces a significant pharmacological advantage over conventional routes of administration.

UR - http://www.scopus.com/inward/record.url?scp=0023205530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023205530&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 829

EP - 832

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 B

ER -